EA201692515A1 - Новая фармацевтическая композиция на основе софосбувира и рибавирина - Google Patents
Новая фармацевтическая композиция на основе софосбувира и рибавиринаInfo
- Publication number
- EA201692515A1 EA201692515A1 EA201692515A EA201692515A EA201692515A1 EA 201692515 A1 EA201692515 A1 EA 201692515A1 EA 201692515 A EA201692515 A EA 201692515A EA 201692515 A EA201692515 A EA 201692515A EA 201692515 A1 EA201692515 A1 EA 201692515A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ribavirin
- pharmaceutical composition
- sofosbuvira
- basis
- new pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение представляет собой новую фармацевтическую композицию, содержащую софосбувир и рибавирин в качестве активных средств по меньшей мере с одним фармацевтически приемлемым вспомогательным веществом, где по меньшей мере одно из активных средств находится в форме с контролируемым высвобождением, для применения в лечении инфекций, вызванных вирусом гепатита С, хронического гепатита С, гепатоцеллюлярной карциномы или пациентов с заболеванием печени на конечной стадии, ожидающих трансплантацию печени.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR201407272 | 2014-06-23 | ||
TR201407287 | 2014-06-24 | ||
TR201407592 | 2014-06-30 | ||
PCT/EP2015/063963 WO2015197549A1 (en) | 2014-06-23 | 2015-06-22 | A novel pharmaceutical composition of sofosbuvir and ribavirin |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201692515A1 true EA201692515A1 (ru) | 2017-05-31 |
Family
ID=53476747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201692515A EA201692515A1 (ru) | 2014-06-23 | 2015-06-22 | Новая фармацевтическая композиция на основе софосбувира и рибавирина |
Country Status (4)
Country | Link |
---|---|
US (1) | US20170151272A1 (ru) |
EP (1) | EP2959888A1 (ru) |
EA (1) | EA201692515A1 (ru) |
WO (1) | WO2015197549A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ2015443A3 (cs) * | 2015-06-26 | 2017-01-04 | Zentiva, K.S. | Farmaceutická formulace sofosbuviru |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
US4614719A (en) | 1982-04-30 | 1986-09-30 | Yamasa Shoyu Kabushiki Kaisha | Process for producing ribavirin |
BE902199A (fr) | 1984-10-29 | 1985-07-31 | Vira Tek Inc | Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide. |
WO2006131790A2 (en) * | 2005-06-09 | 2006-12-14 | Flamel Technologies | Oral ribavirin pharmaceutical composition |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
UY33312A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidato de nucleosido de purina |
BR112014010295A2 (pt) * | 2011-10-31 | 2017-04-18 | Gilead Pharmassett Llc | métodos e composições para o tratamento de vírus de hepatite c |
ES2817886T3 (es) * | 2011-11-29 | 2021-04-08 | Gilead Pharmasset Llc | Composiciones y métodos para tratar el virus de la hepatitis C |
EP2809334A4 (en) * | 2012-02-01 | 2015-06-24 | Abbvie Inc | ONCE DAILY TREATMENT OF HEPATITIS C WITH RIBAVIRIN AND TARIBAVIRIN |
EA201692507A1 (ru) * | 2014-06-23 | 2017-04-28 | Сановель Илач Санайи Ве Тиджарет А.Ш. | Фармацевтические комбинации софосбувира и рибавирина |
EP2959891A1 (en) * | 2014-06-23 | 2015-12-30 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of sofosbuvir and ribavirin |
-
2015
- 2015-06-22 EA EA201692515A patent/EA201692515A1/ru unknown
- 2015-06-22 US US15/320,054 patent/US20170151272A1/en not_active Abandoned
- 2015-06-22 EP EP15173110.6A patent/EP2959888A1/en not_active Withdrawn
- 2015-06-22 WO PCT/EP2015/063963 patent/WO2015197549A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
EP2959888A1 (en) | 2015-12-30 |
WO2015197549A1 (en) | 2015-12-30 |
US20170151272A1 (en) | 2017-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890731A1 (ru) | Модуляторы корового белка гепатита b | |
MX2019003525A (es) | Moduladores alostericos de proteina nucleo de hepatitis b. | |
CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
CL2016000952A1 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
EA201690556A1 (ru) | Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций | |
MX2017008720A (es) | Derivados y metodos para tratamiento de las infecciones por hepatitis b. | |
EA201690979A1 (ru) | Производные азепана и способы лечения инфекций гепатита в | |
CL2015000784A1 (es) | Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades. | |
EA201592081A1 (ru) | СОЕДИНЕНИЯ НА ОСНОВЕ МИКРО-РНК И СПОСОБЫ МОДУЛИРОВАНИЯ АКТИВНОСТИ miR-122 | |
EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
EA201792235A1 (ru) | Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение | |
PH12019501018A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
MX2015017953A (es) | Metodos para tratar el virus de hepatitis c. | |
RS53911B1 (en) | TREATMENT IN HEPATITIS B VIRUS INFECTION ONLY OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND THE DISEASES OF THE LIVER | |
AR094707A1 (es) | Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2 | |
EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
CL2015003431A1 (es) | Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales | |
EA201692514A1 (ru) | Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением | |
PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
EA201692507A1 (ru) | Фармацевтические комбинации софосбувира и рибавирина | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
EA201692515A1 (ru) | Новая фармацевтическая композиция на основе софосбувира и рибавирина | |
MX2014014878A (es) | Combinacion de agentes terapueticos para tratar infeccion por el virus de la hepatitis c (hcv). | |
CL2016002361A1 (es) | Compuestos derivados de azabenzofurano; composición farmacéutica, y su uso como inhibidores de la función de la proteína ns5b del hcv para el tratamiento de la hepatitis c. |